Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV‑2 Main Protease

The coronavirus disease pandemic is a constant reminder that global citizens are in imminent danger of exposure to emerging infectious diseases. Therefore, developing a technique for inhibitor discovery is essential for effective drug design. Herein, we proposed fragment molecular orbital (FMO)-base...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of chemical information and modeling 2022-03, Vol.62 (6), p.1498-1509
Hauptverfasser: Hengphasatporn, Kowit, Wilasluck, Patcharin, Deetanya, Peerapon, Wangkanont, Kittikhun, Chavasiri, Warinthorn, Visitchanakun, Peerapat, Leelahavanichkul, Asada, Paunrat, Wattamon, Boonyasuppayakorn, Siwaporn, Rungrotmongkol, Thanyada, Hannongbua, Supot, Shigeta, Yasuteru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The coronavirus disease pandemic is a constant reminder that global citizens are in imminent danger of exposure to emerging infectious diseases. Therefore, developing a technique for inhibitor discovery is essential for effective drug design. Herein, we proposed fragment molecular orbital (FMO)-based virtual screening to predict the molecular binding energy of potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitors. The integration of quantum mechanical approaches and trajectory analysis from a microsecond molecular dynamics simulation was used to identify potential inhibitors. We identified brominated baicalein as a potent inhibitor of the SARS-CoV-2 main protease and confirmed its inhibitory activity in an in vitro assay. Brominated baicalein did not demonstrate significant toxicity in either in vitro or in vivo studies. The pair interaction energy from FMO-RIMP2/PCM and inhibitory constants based on the protease enzyme assay suggested that the brominated baicalein could be further developed into novel SARS-CoV-2 protease inhibitors.
ISSN:1549-9596
1549-960X
DOI:10.1021/acs.jcim.1c01304